Nicolas Sayegh, MD, University of Utah, Salt Lake City, UT, provides an overview of the survival outcomes and characterization of patients with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response. Only a minority of patients with mCSPC do not achieve an optimal PSA response with intensified ADT. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.